Oratec 74% Stock Increase In January Backed By IDET Payment Prospects
This article was originally published in The Gray Sheet
Executive Summary
Oratec Interventions' stock began to heat up in January, advancing 74% or 3.13 points to 8.94, as investors took note of new data that is expected to support favorable reimbursement for the firm's SpineCath IDET intradiscal electrothermal therapy system by managed care organizations.